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Oral complications are a common side effect of cancer chemotherapy, as antineoplastic agents affect
boththe immune system and the oral mucosa. This studydemonstrates preventive and therapeutic effects
of dental treatment and regular use of Weleda Ratanhia-Mundwasser (herbal mouthwash) and Weleda
Pflanzen-Zahngel (herbal toothgel) on oral mucositis during chemotherapy. Thirty-two female patients
with breast cancer starting on chemotherapy were evaluated in this study. Plaque index, gingival index,
degree of mucositis and 10 single symptoms were monitored once weekly for four consecutive weeks.
After four weeks, plaque and gingival indexes were slightly decreased compared to baseline values. The
degree of mucositis was increased by one grade in 15.6 % of the patients and over 70 % remained
without symptoms. On the whole, single symptoms decreased from day 7 since beginning of
chemotherapy to day 28. Mucositis symptoms were moderate in severity, and the results indicate a
positive influence of using Weleda Ratanhia-Mundwasser and Weleda Pflanzen-Zahngel. Further
studies might be promising.
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Background
Inflammatory changes of the oral mucosa are a common side
effect of cancer chemotherapy. According to the guidelines for
prophylaxis and therapy of mucositis (1) of 2004, the risk to
develop a grade 3 (severe) or grade 4 (life threatening) oral
mucositis lies between 2 and 66%, depending on the type of
chemotherapy (without additional radiotherapy), and between
1 and 53% depending on the type of tumor. In more than one-
third of the patients who develop a grade 3 or 4 oral or
gastrointestinal mucositis, the start of the next chemotherapy
cycle needs to be delayed (1), resulting in impaired cancer
treatment.
Most of the cytostatic agents used for antitumor treatment
exert their toxic properties especially on rapidly proliferating
cell lines. Basal cells of the oral mucosa show a high rate of
proliferation which is comparable to that of tumor cells. This is
why chemotherapy affects both the oral mucosa by decreasing
the regeneration of basal cells (2) and the immune system as a
result of myelosuppression. Both factors together promote the
development of diverse inflammatory changes in the oral
mucosa under chemotherapy, will be summarized as ‘muco-
sitis’ (3). Even if the underlying interactions on the level of
molecular immunology are not yet completely understood,
there is some evidence that e.g. the administration of GM-CSF
(granulocyte-macrophage colony stimulating factor) results in
clinically relevant improvement of mucositis (4). It has been
shown that individual oral hygiene has considerable influence
on symptom presence and severity of oral mucositis (5).
Common dental care products offer several different active
ingredients to reduce bacterial counts and plaque. Fluorides
have antibacterial (sodium fluoride, amine fluoride, tin
fluoride) (6) and plaque decreasing effects (amine
fluoride and tin fluoride). Chlorhexidine is antimicrobial and
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of side effects (e.g. mucosal irritation) it is not advised for
long-term use (7,8). The same holds true for sanguinarine,
which is an antimicrobial alkaloid extracted from Canada
Bloodroot or Paccoon plants (Sanguinaria canadensis) (9).
Kationic detergents such as cetylpyridiniumchloride
have antimicrobial and plaque-inhibiting effects (8), and
so do some volatile oils such as menthol, eucalyptol and
thymol (10).
The principal active ingredients of the preparations used in
this study are extracts from rathania root and myrrh, which are
indicated as phytotherapeutics for local treatment of slight
inflammations of the mucous membrane in mouth and larynx.
In Germany, those extracts are approved by the authorities as
‘Standardzulassung’ (11). The primary effect of ratanhia
(Krameria triandra) root extracts is tissue astringency. Myrrh
tincture, an alcoholic solution of commiphora resins, shows
additional antibacterial properties (12).
Further ingredients of Weleda Ratanhia-Mundwasser
(ratanhia mouthwash) are horse chestnut extract, volatile oils
to stimulate the mouth mucosa and homeopathic components
used in anthroposophic medicine to strengthen dental structure
and to promote tooth enamel production (Fluoride of Calcium
D10, Argentum vitr. D15, Sulfate of Magnesium D20, horse
chestnut bark D20).
Weleda Pflanzen-Zahngel (herbal dentifrice, toothgel)
contains extracts from ratanhia roots, myrrh and chamomile,
delivering a broad range of effects with primarily anti-
inflammatory, antibacterial and lesion healing properties
(13,14). Volatile oils (from peppermint, spearmint and fennel
seeds) are supposed to stimulate the mucosa.
It is the aim of this prospective study to document the effects
of dental treatment and regular use of Weleda ratanhia
mouthwash and herbal dentrifice on incidence and severity of
oral mucositis under chemotherapy.
Methods
This study was conducted at the Poliklinik fu ¨r Zahnerhal-
tungskunde with patients of the Klinikum fu ¨r Frauenheilkunde
(Clinic for female health) of Johannes Gutenberg-University in
Mainz, Germany. All participants were scheduled for indivi-
dual adjuvant chemotherapy after surgery of breastcancer. The
study was designed as a controlled trial with a patient’s choice
at study entry for participation in the medication or in the
control group.
Study conduct
Each patient underwent a total of five dental investigations
by the same treating dentist. A baseline visit was scheduled
immediately before the beginning of the first chemo-
therapy cycle, followed by three investigations under
treatment in weekly intervals and a study termination visit
at week four.
At the baseline visit, the patients’ ages, types of
chemotherapy and their usual intake of alcohol and nicotine
were registered. A dental examination established baseline
DMF-T index (Diseased, Missing, Filled Teeth, max. 28),
plaque index (after to Silness and Lo ¨e, grades 0–3, buccal
tooth surfaces) and gingiva index (after Lo ¨e and Silness,
grades 0–3, 4 points of measurement, highest grade per tooth).
Moreover, a visual assessment method (mucositis grading
grades 0–3, after Carl and Emrich) was used to describe the
extent of oral tissue damage (Table 1). Only the Ramfjord
teeth (nos. 16/21/24/36/41/44) were evaluated for the
parameters depicting oral hygiene status (plaque index and
and gingiva index).
Before iniating the study, all patients were subjected to a
baseline professional tooth cleaning. Each patient was given a
soft bristle toothbrush and the study products, Weleda
Table 1. Grading of indices
Plaque index according to Silness and Lo ¨e
Grade 0 No plaque (visual inspection and periodontal probing)
Grade 1 Thin plaque attachments at the gingival margins on probing
Grade 2 Moderate plaque attachments at the gingival margins, visible to the eye, interdental spaces free
Grade 3 Marked plaque at the gingival margins, interdental spaces filled with plaque
Gingiva index according to Lo ¨e and Silness
Grade 0 Normal gingiva, no inflammation, no reddening, no bleeding
Grade 1 Slight inflammation, slight reddening, no bleeding
Grade 2 Moderate inflammation, redness, edema, bleeding on probing
Grade 3 Severe inflammation, redness, edema, tendency to spontaneous bleeding, ulceration left
Mucositis index according to Carl und Emrich WHO / NCI
Grade 0 None None
Grade 1 Mild Mild
Grade 2 Moderate Moderate
Grade 3 Severe Severe
Grade 4 — Life threatening
Grade 5 — Fatal
362 Herbal preparations for oral mucositisPflanzen-Zahngel and Weleda Ratanhia-Mundwasser (herbal
dentrifice and herbal mouthwash, as described above). Only
these products were to be used for oral care, three times daily,
during the four week study period. In order to ensure patient
compliance they were asked to choose their preferred
treatment.
Assessments
Afterstartofchemotherapytreatment,weeklydentalinvestiga-
tions were scheduled to determine grade of mucositis, plaque
index and gingival index. Furthermore, the following
symptoms were evaluated in patient interviews and visual
examinations: desquamation, mucosal lesions and ulcerations,
gum bleeding, mucosal redness, irritation/ burning sensations
at mucosa and tongue, dry mouth, diminished tasting sense,
problems with food intake and herpes simplex virus infections.
The signs and symptoms were classified as ‘yes’, ‘no’ or
‘slightly’. All above assessments—indices and symptom
severity evaluations—were repeated at the week four study
termination visit. Moreover, the patients were asked to self-
assess the severity changes of their symptoms in the course of
the observation period, their experience of symptom mitiga-
tion immediately after mouthwash application, and total
symptom mitigation. They were also asked to comment on
the taste of the mouthwash and if they would continue to use
the products. Finally they were asked whether they would
advocate intensified dental assistance during and after
chemotherapy.
Statistics
All data were subjected to statistical analysis using descriptive
statistics i.e. mean, median, standard deviation, minimum,
maximum, using the computer program SPSS. Due to the
exploratory approach, no null hypothesis was set to be tested.
Results
Since all 49 patients who were eligible insisted on
participation in the active group, no control group could be
established. This bias had unfortunately to be accepted,
since blinding was impossible due to the astringent effects
and the typical taste of the herbal ingredients, and active
compliance of the patients was required to ensure correct
administration.
Due to their poor overall condition (cancer patients), only
32 of the 49 patients enrolled in the medication phase were
able to attend to all five study visits. Only these patients were
included in the analysis (Table 2).
Baseline characteristics: more than 90% of the
patients had intact mucosae without pathological
alterations
The mean age was 58.9 (±8.9) years. The majority of patients
were classified as low consumers of alcohol and nicotine;
81.3% were non-smokers; 9.4% consumed no alcohol, 43.8%
seldom and 40.6% occasionally; 15.6% of the patients
conceded to regular consumption of tobacco products and
3.1% to regular consumption of alcoholic beverages. One
patient refused to comment.
The drugs used for the underlying breast cancer chemother-
apy were carboplatin, cyclophosphamide, epirubicin and taxol,
which were administered either as single agents or
in combination chemotherapy. The mean DMF-T index of
the patients when the study began was 18.87 (±5.96). Before
the beginning administration of chemotherapy, >90% of the
patients presented intact mucosae without pathological altera-
tions at the baseline visit (Fig. 1).
Efficacy: Both plaque and gingival index were reduced
compared to baseline values
At study termination, >70% were free of symptoms and 8 of
32 patients (25%) were diagnosed with grade 1 mucositis. Of
those, 5 had progressed from grade 0, and 2 had regressed from
baseline grade 2. Thus, mucositis severity was increased by
one grade in 15.6% of all patients. During the observation
period, no patient developed grade 3 oral mucositis.
Both plaque index and gingival index were reduced after the
study period compared to baseline values. Plaque index first
declined from 0.90 (±0.50) at baseline to 0.66 (±0,53), to then
continually increase over time up to 0.84 (±0.39). Mean
gingival index declined to 0.74 (±0.64) from 0.87 (±0.70) after
an intermittent slight increase (Fig. 2).
Tolerability: Adverse symptoms markedly improved by
day 28
None of the adverse events that developed during the first
week of chemotherapy was present at the baseline visit
(Fig. 3). The adverse events that were most common at day
7 visit included dry mouth (64.5%), impaired sense of taste
(38.7%), burning sensations at the mucosa (22.6%) and at the
Table 2. Patient baseline demography
No. Percentage Mean Median SD Min. Max. n
Patients(total) 49
Dropouts 17
PP 32 100
Females 32 100 32
Age (years) 58.9 8.9 34 72 32
DMF-T Index 18.87 19.00 5.96 5.00 28.00 32
Plaque index 0.87 0.92 0.50 0 2.20 30
Gingiva index 0.90 0.74 0.70 0 2.60 30
Mucositis grading
Grade 0 29 90.6
Grade 1 1 3.1
Grade 2 2 6.3
Grade 3 0 0.0
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symptoms were markedly improved (Fig. 4). Only 35.5% of
the patients still complained about dry mouth, the others
experienced only slight or no discomfort. A similar develop-
ment was noted with burning sensations, diminished sense of
taste and ulcerations.
A slight increase was observed in gingival bleeding and
mucosal redness. Slight or no changes were observed for
desquamation, difficulties with food intake, and herpes virus
infections.
Subjective impressions: 93% of patients considered
continuing using the intervention after the study
Asked for their subjective assessments, 13.3% of the patients
stated an overall improvement in total signs and symptoms
between day 7 and day 28, whereas 86.7% indicated no
change. Immediately after administration of the mouthwash,
about half of them experienced subjective mitigation of their
individual complaints. On the whole, more than a third of them
(36.7%) assessed the mitigating effects of the mouthwash as
‘good’ and more than half (56.7%) as ‘satisfactory’. 6.7%
noted less gingival bleeding. The mouthwash’s taste was
termed ‘refreshing’ (46.7%) or ‘neutral’ (40.0%) by most
patients, resulting in an overall opinion of ‘good’ (about half of
the patients) or ‘satisfactory’ (another 30%) taste. Almost all
patients (93.3%) considered continuing use of Weleda
Pflanzen-Zahngel and Weleda Ratanhia-Mundwasser
after termination of the study. Intensified dental care and
assistance during chemotherapy was unequivocally judged as
helpful.
Discussion
Our analysis was purely documentary in intention, not
interventive. Additionally, incidence and severity of oral
complications under chemotherapy strongly depend on the
type of agents used, the therapeutical regimen administered,
and on the patients’ individual baseline conditions (5). Still,
considering the extensive and detailed representation of
mucositis in the abovementioned guidelines (1), a relative
appraisal of the results of this study is deemed essential.
Professional tooth cleaning procedures immediately after
the baseline visit served to provide equal and comparable
dental baseline conditions for all participants. In order to
ensure consistency in the evaluation of the dental parameters
and indices, all investigations were conducted by the same
treating dentist. Considering the mean patient age of 58.9
years, the baseline extent of caries as delineated by the DMF-T
index was well within the normal range. Average values in
Germany were listed as 16.1 for 35–44 year old persons and as
23.6 for 65–74 years of age in 1997 (15).
Both plaque and gingiva indexes were below baseline values
after four weeks of treatment and thus demonstrated good
oral hygiene effectiveness of thrice daily administration of
Weleda Rantanhia mouthwash and Weleda herbal tooth gel.
As expected, the patients showed various signs of damage
of oral mucosal cells during the first week of chemotherapy.
This is a common fact with cytostatic agents that are known to
harm all kinds of mucosal cells. Until the final observation
visit after four weeks, they tended to recede in spite of
continued chemotherapy with the exceptions of gingival
bleeding and mucosal redness, rendering an overall positive
development.
More than 70% of the patients remained asymptomatic of
mucositis even after four weeks. In only 15.6% of all patients
mucositis was increased in severity by one degree, only one
patient presented grade 2 severity and none grade 3.
On the whole, the symptoms could be described as moderate
in severity. A basis for comparison is found which names a
relative risk for developing grade 3 or 4 mucositis of 3 to 13%
after administration of the cytostatic drugs that were observed
(1). The overall risk for breast cancer patients was mentioned
as being 8%.
Since for these data, as fornon-study patients, basic common
oral hygiene can be safely assumed, the observed mildly
positive effects are probably due to thrice daily astringent
mouthwash administration, which is not part of everyday
dental care routine.
On the other hand, it is highly improbable that the observed
symptoms of oral mucositis were caused by the mouthrinse
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Figure 1. Prevalence and severity of mucositis, grades 0–3, at baseline and
termination examinations, (n ¼ 32).
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Figure 2. Changes in mean values of Plaque index (P) and Gingiva index (G)
over time grades 0 to 3 (Baseline examination; week 1, 2, 3 ¼ study week
visits; week 4 ¼ final examination).
364 Herbal preparations for oral mucositisitself. It is generally known that oral mucositis is an almost
inevitable side effect of cancer chemotherapy. On the other
hand, this mouthwash is widely sold all over Europe for
normal daily oral hygiene and has not been reported to cause
such side effects in thousands of administrations.
In their self-assessments, none of the patients complained
about worsening symptoms between day 7 and day 28 of
chemotherapy. Most patients (86.7%) judged the severity as
unchanged, and 13.3% experienced some degree of relief.
Almost all patients (93.3%) wanted to continue the use
of the herbal mouthwash and tooth gel, and all of them
voted in favor of professional dental assistance under
chemotherapy.
Paralleling these results, the mucositis guidelines stress the
necessity of basic oral hygiene and the efficacy of oral care
under professional guidance (oral care protocols and patient
guideline, evidence level III b) (16).
The results of this study suggest that the use of Weleda
Ratanhia mouthwash and Weleda herbal dentrifice may
have a positive influence on the oral side effects of cancer
chemotherapy, and that further investigations might be
desirable.
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